Dear Colleagues,

Genitourinary tumors are common neoplasms that include prostate cancer, kidney cancer, bladder cancer, testicular cancer, and cancers of the penis. Each of those cancers is recognized as a heterogeneous disease, and the clinical course is unique to every patient in terms of prognosis and treatment response. With the rapid advancement in the medical field and the wide use of next-generation sequencing techniques to understand cancer, researchers and physicians are moving away from a “one size fits all” strategy in treating the disease to identifying novel biomarkers that can be targeted to specifically treat every patient. Nevertheless, the treatment of most patients with genitourinary cancers requires a multimodality approach that includes surgical intervention, radiation therapy, and chemotherapy.

It is thus crucial to decipher the molecular and cellular mechanisms underlying the initiation and progression of those intractable cancers and accordingly identify the unique biomarkers associated with them to aid in diagnosis and improve prognosis. This approach to the management of genitourinary cancers by applying basic and translational research with bed-side clinical research is the hub for “personalized medicine” in the 21^st century and it is an area of great interest to physicians and researchers working in the field, in particular molecular pathologists, and hematology-oncologists. This issue focuses on research and experiences related to cancers of the genitourinary system. This may include deciphering the mechanisms underlying the initiation and progression of genitourinary cancers, including:

pathophysiology; molecular, and cellular mechanism identification of novel cancer biomarker therapeutic targets; improving personalized cancer care using new technologies enhancing cancer diagnoses, management, and outcomes. We invite researchers in molecular pathology, hematology-oncology, genitourinary pathology, stem cells, and other fields of cancer research to submit high-quality reviews related to the issues in this research area.

Dr. Hisham Bahmad
Dr. Wassim Abou-Kheir
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Diseases is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• prostate cancer
• bladder cancer
• genitourinary
• biomarkers
• therapeutic target
• personalized medicine
• targeted therapy
• genetic aberrations
• molecular signatures
• next generation sequencing
• modeling
• organoids